Growing evidence suggests that TP53 abnormalities are associated with poor responses to chemoimmunotherapy in chronic lymphocytic leukemia and, to a lesser extent, to novel treatments in WM. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.